Methotrexate vs cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: A single-center analysis in Japan

Y. Koga, Y. Nagatoshi, Y. Kawano, J. Okamura

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The efficacy of methotrexate (MTX) as a single graft-versus-host disease (GVHD) prophylaxis agent was compared to that of cyclosporin A (CSA) in 62 pediatric patients (median age: 8 years) with hematological malignancies who had undergone bone marrow transplantation (BMT) from HLA-identical sibling donors at National Kyushu Cancer Center since 1977. In all, 30 patients received MTX by intravenous bolus injection, with a dose of 15 mg/m2 on day + 1, followed by 10 mg/m2 on days + 3, + 6, and + 11, and then once a week until day + 100. A total of 32 patients were treated with CSA, which was given intravenously in the early stages and orally thereafter until day + 100, and then gradually tapered and stopped 6 months after BMT. There were no differences between the groups in terms of rates of hematopoietic recovery after BMT. The probabilities of acute GVHD (grades II-V) and chronic GVHD were 29.6 vs 40.6% (P = 0.294) and 19 vs 20% (MTX vs CSA), respectively. Relapse rates and event-free survival were identical. These results suggest that MTX and CSA were equally effective when given after BMT in Japanese pediatric patients with hematological malignancies. Since MTX was given over a shorter time than CSA, it might be more practical in the management of such patients.

Original languageEnglish
Pages (from-to)171-176
Number of pages6
JournalBone Marrow Transplantation
Volume32
Issue number2
DOIs
Publication statusPublished - Jul 1 2003
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Methotrexate vs cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: A single-center analysis in Japan'. Together they form a unique fingerprint.

  • Cite this